Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells

Investigational New Drugs

Volumn 19, Issue 3, 2001, Pages 219-227

  Fukuoka, Kazuya ^a,b   Usuda, Jitsuo ^a   Iwamoto, Yasuo ^a   Fukumoto, Hisao ^a   Nakamura, Takashi ^a   Yoneda, Takahiro ^b   Narita, Nobuhiro ^b   Saijo, Nagahiro ^a   Nishio, Kazuto ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cell cycle; E7070; G1 arrest; Lung cancer cells; Resistant cells; Sulfonamide

Indexed keywords

ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; CYCLIN A; CYCLIN B1; CYCLIN DEPENDENT KINASE 2; INDISULAM; PROTEIN P21; PROTEIN P53; SULFONAMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CATALYSIS; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; TUMOR CELL; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; PHOSPHORYLATION; RETINOBLASTOMA PROTEIN; SULFONAMIDES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034843846     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010608317361     Document Type: Article

References (36)

1. Relation between structure and biological activity of sulfonamides
2. Novel sulfonamides as potential, systemically active antitumor agents
3. Phase I study of E7010
4. Mechanism of action for E7010, an orally active sulfonamide antitumor agent: Inhibition of mitosis by binding to the colchicine site of tubulin
5. Preferential binding of E7010 to murine, β3-tubulin and decreased,β3-tubulin in E70101-resistant cell lines
6. A novel antitumor agent, ER-35744, targeting G1 phase. I. Drug discovery and overview of preclinical studies
7. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle
8. A novel antitumor agent, ER-35744, targeting G1 phase. II. Antitumor activities in vitro and in vivo
9. Cancer cell cycles
10. Cyclins and cancer II: Cyclin D and CDK inhibitors, come of age
11. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells
12. The retinoblastoma protein and cell cycle control
13. cdc2 protein kinase in human lung-cancer cells
14. Reversible tyrosine phosphorylation and cell cycle control
15. Cdc2 regulatory factors
16. Oncoprotein signalling and mitosis
17. Detection of a novel cell cycle-regulated kinase activity that associates with the amino terminus of the retinoblastoma protein in G2/M phases
18. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: Characterization and mechanisms of resistance
19. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
20. INK4B/MTS2, and p18 genes in primary and metastatic lung cancer
21. Senderowicz A: Cyclin-dependent kinases: Initial approaches to exploit a novel therapeutic target
22. Okuyama A: A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of Rb protein and cell cycle progression
23. Flavopiridol induces G1 arrest with inhibiton of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells
24. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibitor on CDK2 kinase activity
25. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5
26. The kinase inhibitor staurosporine induces G1 arrest at two points: Effect on retinoblastoma protein phosphorylation and cyclin-dependent kinase 2 in normal and transformed cells
27. Cell cycle arrest and inhibiton by the protein kinase antagonist UCN-01 in human breast carcinoma cells
28. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of middle to late G1 phase of the cell cycle
29. Inhibition of cyclin D1 expression and phosphorylation of retinoblastoma protein by phosmidosine, a nucleotide antibiotic
30. Inhibition of G1 cyclin expression in normal rat kidney cells by inostamycin, a phosphatidylinositol synthesis inhibitor
31. Neuronal differentiation of neuro 2a cells by inhibitors of cell cycle progression, trichostatin A and butyrolactone I
32. The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors A potential mechanism for GGTI-298 antitumor activity
33. A novel antitumor agent ER-35744, targeting G1 phase. III. Studies of mechanism of action
34. 16INK4 expression enhances CPT-11-induced apoptosis through increased delay in S-phase progression in human non-small-cell-lung-cancer cells
35. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function